{"id":5505,"date":"2016-06-17T22:21:49","date_gmt":"2016-06-17T22:21:49","guid":{"rendered":"https:\/\/www.olartemoure.com\/web\/en\/om-weekly-digest-17-06-2016\/"},"modified":"2017-04-25T21:25:55","modified_gmt":"2017-04-25T21:25:55","slug":"om-weekly-digest-17-06-2016","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/","title":{"rendered":"OM Weekly Digest (17-06-2016)"},"content":{"rendered":"<p><img decoding=\"async\" class=\"aligncenter size-full wp-image-6258\" src=\"https:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01.jpg\" alt=\"\" width=\"800\" height=\"108\" srcset=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01.jpg 800w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-300x41.jpg 300w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-768x104.jpg 768w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-461x62.jpg 461w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-260x35.jpg 260w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-50x7.jpg 50w, https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Cabezote2-eng-01-150x20.jpg 150w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">\u00a0<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Patents, Regulatory\u00a0| <strong>For second time in Colombia, a Compulsory License is denied<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">The Ministry of Health and Social Protection <strong>rules out the granting of a Compulsory License for a patent covering the <\/strong><strong>\u03b2<\/strong><strong> polymorph of imatinib (Glivec<\/strong><strong>\u00ae<\/strong><strong>)<\/strong> from Novartis AG, ending the Administrative Procedure for the Declaration of Public Interest (DPI) seeking a Compulsory License.<\/p>\n<p style=\"text-align: justify;\">Specifically, <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/06\/160617-Glivec-Resolucion-2475-de-2016-MinSalud.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Resolution 2475<\/a><\/span> (14 June 2016) declares Imatinib (Glivec\u00ae) as a pharmaceutical of public interest, requesting the National Pharmaceutical Price Commission (NPPC) to consider a new methodology to determine the price of Glivec.<\/p>\n<p style=\"text-align: justify;\">This is the second time that a Compulsory License in Colombia is denied.\u00a0 Previously, it was intended to obtain a Compulsory License for Kaletra\u00ae Antiretroviral, denied by Regulation 1444 (8 May 2009).<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA| Intellectual Property\u00a0| <strong>Superintendence of Industry and Commerce introduces a new online IP system: deadlines will be suspended<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/drupal\/noticias\/superindustria-lanza-sipi-nuevo-sistema-de-propiedad-industrial\" target=\"_blank\" rel=\"noopener noreferrer\">The new system<\/a><\/span> replaces the current platform, and will be characterized because will allow to perform the entire prosecution digitally.<\/p>\n<p style=\"text-align: justify;\">The implementation of the new system means the replacement of the actual platform, reason for which the SIC will suspend temporarily all procedures in trademarks and patents. \u00a0This implies a terms suspension for all IP procedures before SIC between 1 to 18 July 2016, highlighting the following dates:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Last notification list: 28 June.<\/li>\n<li>Last SIC IP Gazette (No. 765): 30 June.<\/li>\n<li>SIC\u2019s IP physical office closure: 30 June at 16:00 hours (UTC -5).<\/li>\n<li>Actual online system shutdown: 30 June at 23:59 hours (UTC -5).<\/li>\n<li>Start of deadlines suspension: 1 July.<\/li>\n<li>New IP system opening: 18 July.<\/li>\n<\/ul>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/06\/160617-Implementaci\u00f3n-SIPI-SIC.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Here<\/a><\/span> you can see SIC\u2019s new online IP system implementation chronogram.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA | Consumer Law\u00a0| <strong>Colombian Congress evaluates Bill against abuses towards electricity and natural gas domiciliary users<\/strong><\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">The Bill (No. 097 of 2015, from the House of Representatives) seeks the protection of energy and natural gas public services users. \u00a0The Bill will update the Domiciliary Public Services Law (No. 142 of 1994) and wants to ensure a balance in the contractual relationship between public services companies and users.<\/p>\n<p style=\"text-align: justify;\">Its main developments are in equating the conditions of users and providers in domiciliary public services contracts, the establishment of grounds allowing to users ceasing\u00a0execution of these contracts and the definition of criteria on abuse of dominant position.<\/p>\n<p style=\"text-align: justify;\"><a href=\"http:\/\/www.imprenta.gov.co\/gacetap\/gaceta.mostrar_documento?p_tipo=27&amp;p_numero=097&amp;p_consec=44707\" target=\"_blank\" rel=\"noopener noreferrer\">Here<\/a> you can see the last available Bill text, and <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.congresovisible.org\/proyectos-de-ley\/por-medio-de-la-cual-se-modifica-el-estatuto-nacional-de-usuarios-de-los-servicios-publicos-domiciliarios-y-se-dictan-otras-disposiciones-en-materia-de-proteccion-de-los-usuarios-de-servicios-publicos-estatuto-nacional-de-usuarios-de-los-servicios-publicos-domiciliarios\/8165\/#tab=2\" target=\"_blank\" rel=\"noopener noreferrer\">the next link<\/a><\/span> show the issuing process history.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 COLOMBIA\u00a0| Patents, Regulatory\u00a0| For second time in Colombia, a Compulsory License is denied . The Ministry of Health and Social Protection rules out the granting of a Compulsory License for a patent covering the \u03b2 polymorph of imatinib (Glivec\u00ae) from Novartis AG, ending the Administrative Procedure for the Declaration of Public Interest (DPI) seeking [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6251,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[],"tags":[],"class_list":["post-5505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OM Weekly Digest (17-06-2016) - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OM Weekly Digest (17-06-2016)\" \/>\n<meta property=\"og:description\" content=\"\u00a0 COLOMBIA\u00a0| Patents, Regulatory\u00a0| For second time in Colombia, a Compulsory License is denied . The Ministry of Health and Social Protection rules out the granting of a Compulsory License for a patent covering the \u03b2 polymorph of imatinib (Glivec\u00ae) from Novartis AG, ending the Administrative Procedure for the Declaration of Public Interest (DPI) seeking [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2016-06-17T22:21:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-04-25T21:25:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"842\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"headline\":\"OM Weekly Digest (17-06-2016)\",\"datePublished\":\"2016-06-17T22:21:49+00:00\",\"dateModified\":\"2017-04-25T21:25:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/\"},\"wordCount\":374,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-espa\u00f1ol-02.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/\",\"name\":\"OM Weekly Digest (17-06-2016) - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-espa\u00f1ol-02.jpg\",\"datePublished\":\"2016-06-17T22:21:49+00:00\",\"dateModified\":\"2017-04-25T21:25:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-espa\u00f1ol-02.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-espa\u00f1ol-02.jpg\",\"width\":\"842\",\"height\":\"482\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-17-06-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OM Weekly Digest (17-06-2016)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OM Weekly Digest (17-06-2016) - OlarteMoure | Intellectual Property","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/","og_locale":"en_US","og_type":"article","og_title":"OM Weekly Digest (17-06-2016)","og_description":"\u00a0 COLOMBIA\u00a0| Patents, Regulatory\u00a0| For second time in Colombia, a Compulsory License is denied . The Ministry of Health and Social Protection rules out the granting of a Compulsory License for a patent covering the \u03b2 polymorph of imatinib (Glivec\u00ae) from Novartis AG, ending the Administrative Procedure for the Declaration of Public Interest (DPI) seeking [&hellip;]","og_url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2016-06-17T22:21:49+00:00","article_modified_time":"2017-04-25T21:25:55+00:00","og_image":[{"width":842,"height":482,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/"},"author":{"name":"admin","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"headline":"OM Weekly Digest (17-06-2016)","datePublished":"2016-06-17T22:21:49+00:00","dateModified":"2017-04-25T21:25:55+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/"},"wordCount":374,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/","url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/","name":"OM Weekly Digest (17-06-2016) - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg","datePublished":"2016-06-17T22:21:49+00:00","dateModified":"2017-04-25T21:25:55+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-espa\u00f1ol-02.jpg","width":"842","height":"482"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-17-06-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"OM Weekly Digest (17-06-2016)"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/olartemoure.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/5505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=5505"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/5505\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/6251"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=5505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=5505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=5505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}